TRICAN BIOTECHNOLOGY CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
SERAbody Platform
Briefly, Trican Biotechnology harvested and assembled tumor reactive B cell receptors sequences into our proprietary DART library ''Directed and Activated immune Response against Tumors/lesions''.
Next-gen sequencing revealed more than
Briefly, Trican Biotechnology harvested and assembled tumor reactive B cell receptors sequences into our proprietary DART library ''Directed and Activated immune Response against Tumors/lesions''.
Next-gen sequencing revealed more than
Founded Year
2015
Unified Business No.
42631063
Status
Active
Number of Employees
20
Total Paid-in
Capital
253,755,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Trican Biotechnology, founded in 2015, is designing antibodies based on in vitro and in silico tools for in vivo validation. Through open technology integration with our proprietary platform, Trican delivers differentiated antibodies to address disease setting across oncology, immunology, and ophthalmology.
We are actively partnering globally with antibody-drug conjugates (ADCs), drug delivery, and bispecific/multispecific innovators.
We are actively partnering globally with antibody-drug conjugates (ADCs), drug delivery, and bispecific/multispecific innovators.
